These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 35592369)

  • 1. Casirivimab and imdevimab for COVID-19.
    Aust Prescr; 2022 Apr; 45(2):58-59. PubMed ID: 35592369
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
    Osugi Y; Iwata H; Imai Y; Kobayashi D; Hirashima R
    Cureus; 2022 Feb; 14(2):e21882. PubMed ID: 35273850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Casirivimab-Imdevimab Antibody Cocktail in Patients Amidst and Post COVID 19 Treatment: A Retro-Prospective Comparative Study in India.
    Joy AP; Karattuthodi MS; Chandrasekher D; Augustine AT
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.
    Vellas C; Del Bello A; Gaube G; Tremeaux P; Jeanne N; Ranger N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac093. PubMed ID: 35299988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors.
    Yoshida J; Shiraishi K; Tamura T; Otani K; Kikuchi T; Mataga A; Ueno T; Tanaka M
    J Pharm Health Care Sci; 2022 Jan; 8(1):1. PubMed ID: 34980269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19.
    Markovitz NH; Pedersen E; Sachs DL; Bresler SC
    JAAD Case Rep; 2022 Sep; 27():156-158. PubMed ID: 35845347
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
    San Filippo S; Crovetto B; Bucek J; Nahass RG; Milano M; Brunetti L
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac080. PubMed ID: 35299987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
    Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
    Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO provides 2 conditional recommendations for casirivimab-imdevimab combination therapy in COVID-19.
    Dunne C; Lang E
    Ann Intern Med; 2022 Jan; 175(1):JC6. PubMed ID: 34871050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
    Widera M; Wilhelm A; Hoehl S; Pallas C; Kohmer N; Wolf T; Rabenau HF; Corman VM; Drosten C; Vehreschild MJGT; Goetsch U; Gottschalk R; Ciesek S
    J Infect Dis; 2021 Oct; 224(7):1109-1114. PubMed ID: 34223909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients.
    Liu EC; Lee JH; Loo A; Mazur S; Sultan S; Aull M; Lee JB; Muthukumar T; Hartono C
    Kidney Int Rep; 2021 Nov; 6(11):2900-2902. PubMed ID: 34514186
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
    Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
    Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania.
    Stan IV; Miron VD; Vangheli IA; Gheorghiu RM; Streinu-Cercel A; Săndulescu O; Craiu M
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Oct; 63(1635):163-164. PubMed ID: 35050242
    [No Abstract]   [Full Text] [Related]  

  • 15. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
    Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.
    Heustess AM; Allard MA; Thompson DK; Fasinu PS
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34071185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
    Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
    J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
    Luitel P; Vais D; Gidron A
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab335. PubMed ID: 34405092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.